What we are studying
The purpose of this study is to examine the effectiveness of immune checkpoint inhibitors (drugs called ipilimumab, nivolumab, or pembrolizumab), either given alone, or in combination with an experimental immunotherapy drug for melanoma. We want to see if the combination is better than the checkpoint inhibitor given by itself. The checkpoint inhibitors used in this study have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic melanoma.
$50 travel reimbursement for study related visits only (if randomized to the experimental drug)